Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Guy

Internal Medicine Gainesville, FL Medical Doctor

NPI 1386639250 CMS profile 289371

1130 Nw 64Th Ter, Gainesville, FL 32605

Open in the dashboard

General payments

$13,016

575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$862,009

5 holdings reported · through program year 2025

Through program year 2025, Christopher Guy of Gainesville, FL is reported in the CMS Open Payments database as having received $13,016 across 575 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $862,009 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,861 89
2024 General $2,424 89
2023 General $1,944 91
2022 General $2,006 101
2021 General $2,079 86
2020 General $1,002 50
2019 General $1,701 69
2025 Ownership $332,505 1
2024 Ownership $243,837 1
2023 Ownership $133,002 1
2022 Ownership $152,665 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Guy
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Guy were reported at $1,861. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Guy Internal Medicine median Middle half National median
2019 $1,701 $159 $48–$570 $163
2020 $1,002 $119 $33–$402 $114
2021 $2,079 $135 $37–$521 $132
2022 $2,006 $141 $42–$496 $149
2023 $1,944 $149 $45–$519 $160
2024 $2,424 $154 $47–$537 $164
2025 $1,861 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,959 129 payments
  2. Amgen Inc. $1,418 68 payments
  3. Lilly USA, LLC $1,315 79 payments
  4. AstraZeneca Pharmaceuticals LP $1,239 27 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,093 43 payments
  6. Pfizer Inc. $731 46 payments
  7. AbbVie, Inc. $648 24 payments
  8. Amarin Pharma Inc. $429 14 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $370 12 payments
  10. Esperion Therapeutics, Inc. $343 8 payments
  11. Other $3,471 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,911 573 payments
  2. Education $105 2 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $1,357 92 payments
  2. Ozempic $1,239 94 payments
  3. FARXIGA $921 19 payments
  4. MOUNJARO $843 40 payments
  5. EVENITY $821 33 payments
  6. JARDIANCE $706 31 payments
  7. BREZTRI $604 7 payments
  8. ELIQUIS $483 28 payments
  9. Prolia $437 27 payments
  10. NURTEC ODT $411 26 payments
  11. Other $9,534 454 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

3,675

Median for Internal Medicine: 777

Drug cost

$200,110

Median for Internal Medicine: $73,373

Branded share of claims

13.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 58 $52,091
Eliquis Apixaban Brand 36 $36,372
Mounjaro Tirzepatide Brand 22 $27,121
Jardiance Empagliflozin Brand 21 $26,230
Januvia Sitagliptin Phosphate Brand 12 $15,469
Synthroid Levothyroxine Sodium Brand 44 $4,528
Atorvastatin Calcium Generic 349 $2,578
Levothyroxine Sodium Generic 192 $2,574
Potassium Chloride Generic 65 $1,963
Omeprazole Generic 198 $1,852

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$177,065

Of which drugs: $6,756

Medicare patients

389

Average age 76

Services billed

6,911

154 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 34%
Diabetes 32%
Atrial fibrillation 20%
Cancer 17%
Chronic kidney disease 15%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 41 41 $3,355
Vaccine for influenza for injection into muscle 90653 Office 38 38 $3,109

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $203
  • Lilly USA, LLC $95
$298 21 —
MOUNJARO
  • Lilly USA, LLC $212
$212 22 —
VRAYLAR
  • AbbVie, Inc. $146
$146 — —
Wegovy
  • Novo Nordisk Inc $144
$144 — —
EVENITY
  • Amgen Inc. $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record